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Abstract
Summary The aim of this study is to produce an easy to use checklist for general practitioners to complete whenever a woman
aged over 65 years with back pain seeks healthcare. This checklist will produce a binary output to determine if the patient should
have a radiograph to diagnose vertebral fracture.
Purpose People with osteoporotic vertebral fractures are important to be identified as they are at relatively high risk of further
fractures. Despite this, less than a third of people with osteoporotic vertebral fractures come to clinical attention due to various
reasons including lack of clear triggers to identify who should have diagnostic spinal radiographs. This study aims to produce and
evaluate a novel screening tool (Vfrac) for use in older women presenting with back pain in primary care based on clinical
triggers and predictors identified previously. This tool will generate a binary output to determine if a radiograph is required.
Methods The Vfrac study is a two-site, pragmatic, observational cohort study recruiting 1633 women aged over 65 years with self-
reported back pain. Participants will be recruited from primary care in two sites. TheVfrac studywill use data from two self-completed
questionnaires, a simple physical examination, a lateral thoracic and lateral lumbar radiograph and information contained in medical
records.
Results The primary objective is to develop an easy-to-use clinical screening tool for identifying older women who are likely to
have vertebral fractures.
Conclusions This article describes the protocol of the Vfrac study; ISRCTN16550671.
Keywords Vertebral fracture . Screening . Osteoporosis . Protocol
Background and rationale
Osteoporosis is estimated to affect 200 million women world-
wide [1]. Osteoporotic fractures are strongly associated with
morbidity, especially in terms of pain and disability: out of the
people who have had a fracture, 42% have chronic pain and
33% of these describe the pain as severe or unbearable [2].
People who are hospitalised after a vertebral fracture (VF)
have a higher mortality rate following fracture than those
hospitalised after a hip fracture [3]. Unlikemortality following
a hip fracture, mortality after a VF rises progressively after the
event [3]. However, unlike hip fractures, most VFs do not
require hospitalisation. Furthermore, the socioeconomic bur-
den of VF is not as well defined as that of hip fractures, in part
because the epidemiology of VFs is less well established as
there is no universally accepted definition.
Only 25% of VFs result from falls, with the majority caused
by daily activities such as bending forwards, climbing stairs or
lifting objects [4]. People with VFs have a reduced health-
related quality of life that is not solely a result of confounding
by age, nor can it be fully explained by the presence of pain [5].
VF in older people has an effect on everyday activities such as
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reducing their ability to get in and out of a car, lift objects from
the floor, walk a few blocks, climb up and down steps, reach or
extend their arms above shoulder level, prepare meals and do
the shopping [6]. VFs can also deprive people of their social
support because their physical and functional capabilities have
been limited [7]. The presence of VFs increases the risk of
subsequent fractures, especially further vertebral or hip frac-
tures [8], although there are medications available to reduce this
risk [9–11]. Despite this, less than a third of people with oste-
oporotic VFs come to clinical attention [12] due to a variety of
reasons including lack of clear clinical triggers to identify who
should have diagnostic spinal radiographs.
We previously carried out a cross-sectional study of 509
older women from primary care, identifying four clinical trig-
gers that could be combined in a simple tool to determine who
should have spinal radiographs to identify undiagnosed oste-
oporotic VFs: height loss, back pain, previous fracture as an
adult and rib-to-pelvis distance [13]. A cutoff from the regres-
sion equation was subsequently selected which identified all
women with more than one VF and half of those with one VF.
A large randomised controlled trial (RCT) of this screening
tool, Cohort for skeletal health in Bristol and Avon
(COSHIBA), was then undertaken in a primary care popula-
tion of unselectedwomen aged over 65 years [14]; 3200wom-
en were recruited. Allocation to the screening arm approxi-
mately doubled the prescription of osteoporosis medications
at 6 months follow-up. However, preliminary cost-
effectiveness modelling suggested a cost-per-QALY of
£30,000, making it unlikely that this would be cost-effective
from the National Health Service (NHS) perspective in this
setting, in the UK. This was mainly because of a low preva-
lence of VFs in this unselected population. A key finding from
the National Osteoporosis Society into the realities of life with
osteoporosis was that 58% of people with VFs have long-term
back pain [15]. Therefore, we carried out a case-control study
to look more specifically at the population of women aged
over 60 years with back pain [16] to identify self-reported
characteristics of pain that might help predict who has osteo-
porotic VFs. This study identified novel independent predic-
tors of VF including shorter duration of back pain, pain de-
scribed as crushing, pain improving on lying down and pain
not spreading down the legs. Area under the curve (AUC)
statistics for the combination of these factors to identify wom-
en with VFs was 0.85 (95%CI 0.79 to 0.92). Therefore, self-
reported pain descriptives may identify people with back pain
who have a vertebral fracture [16–18]. The Vfrac study com-
bines the original COSHIBA screening tool with the newly
identified pain descriptors (McGill questionnaire and new
qualitative focus group work). Only women over 65 years
with self-reported back pain will be eligible for this study.
The aim of Vfrac is to produce and evaluate an improved
screening tool (Vfrac) for use in older people presenting to
primary care with back pain.
The need for this study
The National Institute for Health and Care Excellence (NICE)
guidelines CG146 [19] state the requirement for a study based
in primary care to assess which people are at high risk of
fracture. The Arthritis Research UK metabolic bone disease
musculoskeletal trauma clinical studies group strategy sug-
gested studies of new methods of detection of vertebral frac-
tures and their effects on quality of life as one of their five
focuses [20]. Furthermore, patients with osteoporosis and
fracture identified earlier identification of osteoporosis as a
top 2 research priority in a UK study of 1188 patients [21].
If Vfrac is deemed to be cost-effective, national implementa-
tion of Vfrac in primary care and local Fracture Liaison Services
is likely to identify more of the currently undiagnosed older
womenwith osteoporotic VFs, who have one of the highest risks
of future fracture [22, 23], and will allow reduction in future
fracture risk by approximately 50% after intervention [24].
Primary aim
The aim of this Arthritis Research UK funded study (ref:
21507) is to produce and evaluate an improved tool (Vfrac)
to screen older women with back pain for osteoporotic verte-
bral fractures.
Design and methods
Outline
The Vfrac study is a multicentre, pragmatic, observational
cohort study with data collection at baseline and 3 months
follow-up. Baseline data collection is by self-report, physical
examination at a research clinic plus spinal radiographs. Data
collection at follow-up is by self-report and from GP electron-
ic records. Table 1 shows the timeline for the study.
A total of 1633 women aged over 65 years will be recruited
via primary care from two sites within England— Bristol and
Stoke-on-Trent. Potential participants will be asked for their
consent via post and asked to fill in a baseline questionnaire
containing items on demographics, socioeconomic status, tra-
ditional risk factors for osteoporosis, back pain, quality of life,
medication use, healthcare utilisation and comorbidity. Upon
the study team’s receipt of the completed baseline question-
naire and consent form, an appointment will be made for the
participant to have a physical examination in secondary care
followed by a lateral thoracic and lateral lumbar radiographs
performed using standard NHS standard operating procedure
on the same day. Before the physical examination, the partic-
ipant will be asked, in person, to sign another consent form. In
this consent process, they will be asked if they agree to the
physical examination and radiograph. The radiograph report
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will be sent to the participant’s general practitioner (GP) as if
the GP had ordered the radiograph. The GP practices will be
given a guidance document upon recruitment, providing infor-
mation on recommended pathway for patients with a vertebral
fracture. This advice has been taken from the North Bristol
NHS Trust guidance for GP practices within BSSG CCG
(Fig. 1). The first step in this guidance is an X-ray to confirm
VF.
A copy of the radiograph and the report will also be sent to
the chief investigator for research analysis after identifying
information has been removed. Three months after the
radiograph, the participant will be asked to complete a
follow-up questionnaire, containing questions about whether
results of the spinal radiograph were communicated to the
patient, whether they started on any new medication, and
whether they have been referred to any healthcare service,
e.g. physiotherapy and quality of life. Data collection from
the participants’ GP electronic records will also be conducted
at this time. This will comprise extraction of information
about current medication, number of contacts with healthcare
practitioners, whether results of the radiograph are recorded in
the notes and concomitant illnesses. The end of study will be
Table 1 Vfrac study timeline
2017 2018 2019 2020 2021
Pre-
funding
Jan–
Mar
Apr–
Jun
Jul–
Sep
Oct–
Dec
Jan–
Mar
Apr–
Jun
Jul–
Sep
Oct–
Dec
Jan–
Mar
Apr–
Jun
Jul–
Sep
Oct–
Dec
Jan–
Mar
Apr–
Jun
Ethics, research governance and
other approvals; staff recruitment
● ● ●
Recruitment of general practices ● ● ●
Recruitment of patients ● ● ● ● ● ● ●
Data collection: self-report
(baseline questionnaire) and
physical examination
● ● ● ● ● ●
Spinal radiographs ● ● ● ● ● ● ●
Statistical analysis ● ●
Generate web-based Vfrac tool ● ●
Identification of stopping rules for
future definitive trial
● ●
Follow-up of patients having
X-rays (follow-up questionnaire
and medical records download)
● ● ● ● ● ● ●
Modelling cost-effectiveness ● ● ●
Dissemination, and preparation
of future pilot application
● ● ● ● ●
Vertebral fracture conﬁrmed on x-ray
Symptomac management Osteoporosis management
Pain VAS > 5/10 at 6 
wks. Reduced 
walking and limited 
acvies of daily 
living (ADL)
Pain VAS < 5/10 at 6 
wks. Walking and 
ADL improving
Refer to 
vertebroplasty clinic
Refer to specialist 
physiotherapy
Invesgaons
Start bone 
protecon
Refer to secondary care 
osteoporosis clinic
Consider referral to physiotherapy, falls and frailty services
Fig. 1 Management of a patient
with an osteoporotic vertebral
fracture. Note: (Manage patients
according to this pathway
provided they have no recent
history of significant back trauma,
no red-flag clinical features to
suggest alternative diagnoses
such as malignancy and are at risk
of osteoporosis (e.g. FRAX score
amber or red—see http://www.
shef.ac.uk/FRAX/tool.jsp)
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the date of receipt of the last follow-up questionnaire of the
last patient. The study flowchart is provided in Fig. 2.
The primary objective is to develop a clinical screening tool
for identifying older women with back pain who are likely to
have VF. The output will be a simple clinical checklist of self-
reported data and data from the physical examination which
will produce a binary assessment of (1) yes—this person needs
a spinal radiograph, or (2) no radiograph needed. The primary
evaluative measure will be the accuracy of the Vfrac tool as
represented by the sensitivity and specificity of > 80%.
Study participant selection
General practices will be recruited from Bristol (9) and Stoke-
on-Trent (16) areas. Practices will be recruited after an open
call in the order they express an interest in the study until the
number of participants target is reached at each site. The fol-
lowing entry criteria will be used for participants:
Inclusion: participant is willing and able to give informed
consent for participation in the study, female, over 65 years
and with self-reported back pain (via baseline questionnaire)
in the previous 4 months.
Exclusion: male, 65 years or under, no self-reported back
pain (via baseline questionnaire) in the previous 4 months, has
already had a full spinal X-ray in the previous 4 months or
considered unsuitable to take part by their GP (e.g. cognitive
impairment, near end of life or recently bereaved).
Sample size
The sample size is based on the following assumptions:
& A prevalence of VFs between 12 and 20%, based on data
from the European Vertebral Osteoporosis Study (EVOS)
[12]. This is based on the general population of women
under 65 years and is, therefore, likely to be lower than the
true prevalence of VFs in older women with back pain.
& A margin of error (that is, the half-width in 95% confi-
dence intervals of sensitivity or specificity) of 5%.
& Sensitivity and specificity of the Vfrac tool between 80
and 95%.
Table 2 shows the range of sample sizes according to prev-
alence of VFs and sensitivity or specificity of the Vfrac tool;
Would like to take 
part in the study
Post invitaon pack (invitaon leer, PIS, consent form and baseline 
quesonnaire).
Would not like to take 
part in the study
No further acon
Return consent form and 
baseline quesonnaire
Aend appointment for 
physical examinaon and 
spinal radiograph
Complete and return 
follow-up quesonnaire 
3 months
GP electronic records 
download 
3 months
(1) Development of the 
clinical tool (Vfrac)
(2) Produce online version 
of Vfrac
(3) Modelling cost-
eﬀecveness
Excluded: Do not 
meet eligibility 
criteria
Fig. 2 Study flowchart
   11 Page 4 of 9 Arch Osteoporos           (2019) 14:11 
wewill aim for a sample size of 1633. This sample size will be
large enough to encompass any specificity of Vfrac as sample
sizes required for specificity are much lower.
Recruitment
Recruitment will be from the community via primary care.
Women over 65 years who can give informed consent and are
not found to be unsuitable for the study by their GP (e.g. are not
housebound) will be sent study invitation packs. The invitation
pack will contain an invitation letter signed by the potential par-
ticipant’s GP, the participant information sheet, two copies of the
first consent form and the baseline questionnaire. The invitation
packs will be sent to the potential participants by their own gen-
eral practitioner. The invitation pack will make it clear that the
studywishes to includewomen over 65 years who have had back
pain in the previous 4 months, even if they have had back pain
for more than 4 months. Reminder letters will be sent after 4–
6 weeks if no response is initially received.
Participants willing to participate will be asked to complete
the baseline questionnaire and one copy of the consent form,
returning these to the researchers using a prepaid envelope.
The consent form will contain a section for the participant to
supply us with their title, name, address, phone number, email
address and contact preferences.
Upon receipt, the completed consent form and baseline ques-
tionnaire will be checked by a study researcher. The first question
in the baseline questionnaire is a screening question: ‘have you
had back pain in the previous 4 months?’. If the participant has
answered ‘no’, then they are not eligible for the study and will be
sent a thank you letter. If a potential participant is eligible, they
will be booked in for a physical examination and spinal radio-
graphs. A research administrator will phone the participant to
make the appointment after ensuring the participant is willing
to continue taking part in the study and has not had a full spinal
radiograph in the previous 4months. Participants will be asked to
give written face-to-face consent for the physical examination
and the radiographs at the research clinic.
Each participant has the right to withdraw from the study at
any time. If any participant loses capacity during the study,
they will be withdrawn but their data to date kept.
Follow-up
Follow-upwill occur 3months after the spinal radiographvia post
and through data collection fromGP electronic records. The par-
ticipantswill receive a follow-up questionnaire and cover letter. If
there is no reply after 2–3 weeks, the participant will receive an-
other follow-up questionnaire and reminder cover letter.
Data collection and analysis
Data collection will occur at baseline via self-report, a physi-
cal examination at a research clinic and spinal radiograph, and
at follow-up via self-report and through GP electronic records.
The items in the questionnaires were chosen based on lit-
erature review and previously published work [13, 14, 16].
The questionnaires will contain the following items:
& Margolis pain diagrams [25] at baseline
& PHQ-9 [26] at baseline and follow-up
& PainDETECT [27] at baseline
& FRAX [28] clinical risk factors only at baseline
& Q-Fracture [29] at baseline
& Diagnosis of osteoporosis at baseline and follow-up
(‘have you ever been diagnosed with osteoporosis (brittle
bones)?’; ‘approximate date of diagnosis’)
& Traditional risk factors of osteoporosis at baseline
& EQ5D-5L [30] at baseline and follow-up
& ICECAP-O [31] at baseline and follow-up
& Items based on focus group work with patients with VFs and
based on the McGill Pain questionnaire [16, 18] at baseline
& Descriptions of pain deemed important during focus group
work (REC reference number16/NS/0110) at baseline
& Use of pain medication at baseline and follow-up
& Current prescription drugs and over the counter medica-
tion/remedies/supplements at baseline and follow-up
& Use of healthcare services at baseline and follow-up
& Whether results of the radiograph were communicated to
the patient at follow-up
During the research clinic, the following information will be
collected: height (stand-alone stadiometer), weight, chest expan-
sion, rib-to-pelvisdistance,wall-tragusdistance andwaist circum-
ference. To calculate height loss, we will be relying on the partic-
ipant to know how tall they were at 25 years. In the baseline
Table 2 Calculation showing range of sample sizes according to
prevalence of vertebral fractures and sensitivity (A) or specificity (B) of
the Vfrac tool
Prevalence of vertebral fractures
12% 15% 20%
Sensitivity
80% 2050 1640 1230
85% 1633 1306 980
90% 1159 927 695
95% 609 487 365
Specificity
280 289 308 80%
232 231 245 85%
158 164 174 90%
83 86 92 95%
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questionnaire, theparticipantsareasked ‘howtallwereyouataged
25?’and ‘howtallareyounow?’.Thesedatawerechosenbasedon
literature reviewandpreviouspublished research [13,14,16].The
Vfrac study chief investigator will have access to all spinal radio-
graphswith the study ID number as the only identifying feature.
Objectives and outcome measures
(1) To develop a clinical screening tool for identifying older
women with back pain who are likely to have VFs. The output
of this aim is a simple clinical checklist likely to consist of
self-reported data and data from physical examination. The
primary evaluative measure will be the accuracy of the
Vfrac tool as represented by the sensitivity and specificity.
The aim is for sensitivity and specificity of > 80% to justify
subsequent evaluation in a definitive trial. Data from the base-
line questionnaire, the physical examination and spinal radio-
graph will be used.
(2) To produce an online version of the combined predic-
tors for easy use as a clinical tool (Vfrac) to identify which
older women with back pain are likely to have a VF and,
therefore, needs a radiograph. The output of this aim is a
web-based online version of the clinical checklist (see primary
objective).
(3) To model the cost-effectiveness of Vfrac based on
follow-up of the participants to identify if a future definitive
cluster randomised controlled trial is appropriate. The output
of this aim will be an estimate of likely cost-effectiveness and
a list of sources of variation that can be tested in a pilot as part
of a future application for funding. Data at follow-up by self-
report plus from GP electronic records will be used.
Analysis of outcome measures—vertebral fractures
All spinal radiographs will be analysed by a trained clinician
researcher for the presence of VFs using the Algorithm-Based
Qualitative (ABQ) approach [32]. Images that are difficult to
interpret via the ABQ method or using automated QMwill be
viewed by the trained clinician researcher (EC) and a spinal
radiologist and consensus reached. In ABQ, the diagnosis of
osteoporotic fracture assumes that these fractures always in-
volve the endplate within the vertebral ring. This method rec-
ognises that short vertebral height is not always due to fracture
[33], but may be developmental or degenerative in origin. As
such, the ABQ is felt to be more specific for true VF, partic-
ularly mild deformities and avoids the high false-positive rate
of quantitative morphometry (QM) [34]. In addition, QM [35]
will also be used to identify VFs as this method is available
within automated software for the analysis of spinal radio-
graphs and has the potential to become more commonly used
within the NHS. However, QM is less specific and is associ-
ated with an increased number of false positives.
Analysis—developing the clinical tool
Data from the questionnaires and physical examination will be
linked to those from the analysis of spinal radiographs for the
presence/absence of vertebral fractures. The first step will be
univariable analyses to identify associations between risk fac-
tors and presence of VFs.Multiple logistic regression analyses
will be performed with the aim of identifying clinical risk
factors that are independently predictive of the presence of
VF. All likely contenders from the univariable analysis will
be included, with variables deleted in a backwards fashion
whilst considering aspects such as clinical interpretation and
associations between the variables, rather than relying on a
simple automated basis. For example, once a final model is
obtained, all deleted variables will be checked one by one to
confirm if they did not contribute further. Hence, the number
of variables to be considered in the multivariable modelling
has not been pre-specified (on, for instance, an events per
variable threshold), but the analyses will be structured, includ-
ing considering variables in cognate groups, so that it is un-
likely that any one model will involve more than 6–10 vari-
ables [36]. Separate analyses will then be performed to iden-
tify a cutoff to predict one or more VFs and more than one VF.
Sensitivity and specificity of the pre-determined threshold will
be calculated using standard techniques, comparing against
the gold standard of identification of VFs from radiographs
by the chief investigator using the ABQ method.
Secondary analyses will involve calculating the AUC to
measure discriminative ability. To provide an estimate of the
validity of the predictive models, 200 bootstrap samples of the
original dataset will be derived (each bootstrap sample will be
generated by randomly sampling from the original dataset
with replacement 505 times). Logistic regression will then
be performed on each bootstrap sample using the same set
of predictor variables as in the final model, and the regression
coefficients and AUC calculated. Each set of bootstrap sample
coefficients will then be used to calculate AUC for the original
dataset. The difference between these estimates will be used to
evaluate the extent to which the discriminative ability of our
final model decreases when applied to other random samples
[37].
Analysis—modelling cost-effectiveness
Ideally, the presence of an osteoporotic VF will result in
formal assessment of future fracture risk and prescription
of medications such as bisphosphonates. Follow-up data
will allow identification of patient pathways after patients
have received their spinal radiograph. This will allow esti-
mation of the number of older women receiving new bis-
phosphonate (or other anti-osteoporosis medications) pre-
scriptions and whether they had any further investigations
(such as a DEXA scan) or additional primary care contacts,
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including physiotherapy after their radiograph. A model-
ling approach will be used to estimate the cost-per-quality
adjusted life year (QALY) if Vfrac is implemented in the
NHS. The EQ-5D data collected during this study will
provide a baseline QALY for older women with back pain
in the UK, as these data are not currently available. Data
from the literature will be used to model the likely differ-
ence in change in QALYs between any future control and
intervention arms. These will be based upon estimated
changes in QALYs including, for example, due to age,
occurrence of osteoporotic fracture, management of back
pain and prescription of medications for osteoporosis.
Without a randomised element, it is not possible to measure
the proportion of women going on to get the correct diagnosis
of VF and appropriate treatment in the absence of the Vfrac
tool. It is, therefore, necessary to explore alternative scenarios
using expert opinion. Opinion of experts in the fields of pri-
mary care, osteoporosis and care of the elderly will be obtain-
ed on likely patient pathways in the absence of Vfrac.
Interviews and group discussions will be undertaken with
physicians, surgeons, GPs and allied health professionals in
the fields of primary care, osteoporosis and care of the elderly
over a 6-month period will provide an estimation of each
likely step in the treatment pathway of women with back pain
occurring in the absence of Vfrac including to estimate costs
of any adverse effects of medications.
As individual-level data will be available, the uncertainty
(variance) of our cost-effectiveness analysis will be estimated
via a probabilistic uncertainty approach using Monte Carlo
Simulat ions in combination with non-parametric
bootstrapping techniques, where appropriate. The quality
and validity of the cost-effectiveness model will be ensured
by (1) basing the structure of the model on previous cost-
effectiveness models in the field of osteoporosis; (2) ensuring
inputs to the model are valid; (3) ensuring modelling is appro-
priated to the future decision-making context of Vfrac (that is,
from the NHS perspective and tailored to CCGs); and (4) the
uncertainty (variance) is clearly identified so it can be tested in
any future pilot study.
Access to data
Direct access will be granted to authorised representatives
from the sponsor and host institution for monitoring and/or
audit of the study to ensure compliance with regulations.
Patients will be asked for permission to share anonymised data
beyond the immediate project team. The data will be deposit-
ed at the University of Bristol Research Data Repository (as
controlled data). A metadata record will be published openly
by the repository and this record will clearly state how data
can be accessed.
Quality assurance procedures
The study will be monitored or audited in accordance with the
currently approved protocol, good clinical practice, relevant
regulations and standard operating procedures of the sponsor.
AVfrac study Steering Committee, with terms of reference as
per the funder’s guidelines, and will meet twice per year be-
tween 1st January 2018 and 30th June 2021. The. The Vfrac
management team will meet monthly.
Ethical and regulatory considerations
The investigator will ensure that this study is conducted in
accordance with the principles of the Declaration of
Helsinki. The chief investigator will ensure that this study is
conducted in accordance with relevant regulations and with
good clinical practice.
Publication policy
Upon study completion, a report will be prepared for the
funding body. The results will be published in peer-
reviewed journals and presented at scientific meetings.
Arthritis Research UK and the University of Bristol’s open
access policies for publication of peer-reviewed papers will
be followed.
The chief investigator and co-applicants will be in-
volved in reviewing drafts of the manuscripts, abstracts,
press releases and any other publications arising from the
study. Authors will acknowledge that the study was funded
by Arthritis Research UK. Authorship will be determined
in accordance with the ICMJE guidelines and other con-
tributors will be acknowledged.
A poster summarising the results will be sent to all GPs
involved with the study to display in their waiting area. Any
patients who give us their email address will be sent a copy of
this poster. A summary of the results will also be posted on the
study webpage: http://www.bristol.ac.uk/translational-health-
sciences/research/musculoskeletal/rheumatology/research/
vfrac-study.html
Conclusion
If successful, this planned cohort study will result in a
simple checklist ready for testing within the NHS to iden-
tify which older women with back pain should have a spi-
nal radiograph as they are at high risk of having a VF.
Correct identification of women with VFs will allow them
to have medications and other treatments to reduce their
risk of future fracture by half [24]. This is likely to have
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substantial impacts on both NHS healthcare costs (by re-
ducing hip fracture costs, for example) as well as improv-
ing quality of life for older people.
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